Kalaris Therapeutics, Inc.
NGM: KLRSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Kalaris Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KLRS Z-Score →About Kalaris Therapeutics, Inc.
Healthcare
Biotechnology
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
📊 Fundamental Analysis
Kalaris Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -308.1%, which indicates that capital utilization is currently under pressure.
At a current price of $6.30, KLRS currently sits at the 43rd percentile of its 52-week range (Range: $2.14 - $11.88).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$144.45M
Trailing P/E
--
Forward P/E
-4.33
Beta (5Y)
--
52W High
$11.88
52W Low
$2.14
Avg Volume
62K
Day High
Day Low